Celldex Therapeutics reported $23.43M in Operating Expenses for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Expenses Change
Abbvie ABBV:US $ 8821M 991M
Agenus AGEN:US $ 61.4M 12.89M
Amgen AMGN:US $ 3.74B 804M
Applied Genetic Technologies AGTC:US $ 13.58M 4.86M
Aptinyx Inc APTX:US $ 19.38M 207K
Biocept BIOC:US $ 22.65M 5.9M
Bristol Myers Squibb BMY:US $ 9.1B 247M
Celldex Therapeutics CLDX:US $ 23.43M 2.76M
Cytrx CYTR:US 1.29M 7.73M
Glaxosmithkline GSK:US 6.98B 1.65B
Immunogen IMGN:US $ 60.93M 1.62M
Merrimack Pharmaceuticals MACK:US $ 132K 341K
Nektar Therapeutics NKTR:US $ 141.38M 3.46M
Newlink Genetics NLNK:US 7.84M 1.05M
Northwest Biotherapeutics NWBO:US 12.28M 1.58M
Pfizer PFE:US $ 15788M 3271M
Rigel Pharmaceuticals RIGL:US $ 43M 1.17M
Seattle Genetics SGEN:US $ 559.51M 42.41M